OncoKB: A precision oncology knowledge base

JCO Precision Oncology

Volumn 2017, Issue 1, 2017, Pages 1-16

  Chakravarty, Debyani ^a   Gao, Jianjiong ^a   Phillips, Sarah ^a   Kundra, Ritika ^a   Zhang, Hongxin ^a   Wang, Jiaojiao ^a   Rudolph, Julia E ^a   Yaeger, Rona ^a   Soumerai, Tara ^a   Nissan, Moriah H ^a   Chang, Matthew T ^a   Chandarlapaty, Sarat ^a,b   Traina, Tiffany A ^a   Paik, Paul K ^a,b   Ho, Alan L ^a   Hantash, Feras M ^c   Grupe, Andrew ^c   Baxi, Shrujal S ^a,b   Callahan, Margaret K ^a,b   Snyder, Alexandra ^a,b   Chi, Ping ^a,b   Danila, Daniel C ^a,b   Gounder, Mrinal ^a,b   Harding, James J ^a,b   Hellmann, Matthew D ^b   Iyer, Gopa ^a,b   Janjigian, Yelena Y ^a,b   Kaley, Thomas ^a   Levine, Douglas A ^a   Lowery, Maeve ^a,b   Omuro, Antonio ^a   Postow, Michael A ^a,b   Rathkopf, Dana ^a,b   Shoushtari, Alexander N ^a,b   Shukla, Neerav ^a   Voss, Martin H ^a   Paraiso, Ederlinda ^a   Zehir, Ahmet ^a   Berger, Michael F ^a,b   Taylor, Barry S ^a   Saltz, Leonard B ^a,b   Riely, Gregory J ^a,b   Ladanyi, Marc ^a   Hyman, David M ^a   Baselga, José ^a,b   Sabbatini, Paul ^a   Solit, David B ^a,b   Schultz, Nikolaus ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CANCER THERAPY; CANCER TISSUE; COPY NUMBER VARIATION; DRUG LABELING; DRUG RESPONSE; EVIDENCE BASED MEDICINE; FACTUAL DATABASE; FOOD AND DRUG ADMINISTRATION; GENE FUSION; GENE MUTATION; HUMAN; INTERNET; MEDICAL DECISION MAKING; MEDICAL EXPERT; ONCOKB; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; SCIENTIFIC LITERATURE; SOMATIC MUTATION;

EID: 85077486246     PISSN: None     EISSN: 24734284     Source Type: Journal    
DOI: 10.1200/PO.17.00011     Document Type: Article

References (100)

1. Weinstein JN, Collisson EA, Mills GB, et al: The Cancer Genome Atlas pan-cancer analysis project. Nat Genet 45: 1113-1120, 2013
2. Hudson TJ, Anderson W, Artez A, et al: International network of cancer genome projects. Nature 464:993-998, 2010 [Erratum: Nature 465:966, 2010]
3. Vanderbilt-Ingram Cancer Center: My cancer genome. https://www.mycancergenome.org
4. Griffith M, Spies NC, Krysiak K, et al: CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat Genet 49:170-174, 2017
5. The McDonnell Genome Institute: CIViC: Clinical interpretations of variants in cancer. https://civic.genome. wustl.edu
6. Huang L, Fernandes H, Zia H, et al: The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations. J Am Med Inform Assoc 10.1093/jamia/ocw148 [epub ahead of print on October 27, 2016]
7. Institute of Precision Medicine: Welcome to the PrecisionMedicine Knowledgebase. https://pmkb.weill.cornell.edu
8. Patterson SE, Liu R, Statz CM, et al: The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies. Hum Genomics 10:4, 2016
9. The Jackson Laboratory: Clinical Knowledgebase (CKB). https://www.jax.org/clinical-genomics/ckb
10. Barcelona Biomedical Genomics Lab: Cancer genome interpreter. https://cancergenomeinterpreter.org
11. Damodaran S, Miya J, Kautto E, et al: Cancer driver log (CanDL): Catalog of potentially actionable cancer mutations. J Mol Diagn 17:554-559, 2015
12. The Ohio State University: CanDL. http://candl.osu.edu
13. Lawrence MS, Stojanov P, Mermel CH, et al: Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:495-501, 2014
14. Broad Institute: Welcome to TumorPortal: Genes, cancers, DNAmutations and annotations. http://tumorportal.org
15. Massachusetts General Hospital: Targeted cancer care. https://targetedcancercare.massgeneral.org
16. Meric-Bernstam F, Johnson A, Holla V, et al: A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107:dvj098, 2015
17. The University of Texas MD Anderson Cancer Center: Personalized cancer therapy knowledge base for precision oncology. https://pct.mdanderson.org
18. Memorial Sloan Kettering Cancer Center: Cancer hotspots. http://cancerhotspots.org
19. Memorial Sloan Kettering Cancer Center: OncoKB. http://oncokb.org
20. Cerami E, Gao J, Dogrusoz U, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401-404, 2012
21. Gao J, Aksoy BA, Dogrusoz U, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1, 2013
22. Memorial Sloan Kettering Cancer Center: cBioPortal for cancer genomics. http://www.cbioportal.org
23. Yao Z, Torres NM, Tao A, et al: BRAF mutants evade ERK-Dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell 28:370-383, 2015
24. Dahlman KB, Xia J, HutchinsonK, et al: BRAF(L597) mutations in melanoma are associated with sensitivity toMEK inhibitors. Cancer Discov 2:791-797, 2012
25. Bowyer SE, Rao AD, Lyle M, et al: Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res 24:504-508, 2014
26. Kim KB, Kefford R, Pavlick AC, et al: Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31: 482-489, 2013
27. Paik PK, Drilon A, Fan PD, et al: Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 5:842-849, 2015
28. Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. Nature 511: 543-550, 2014 [Erratum: Nature 514:262, 2014]
29. Ma PC, Jagadeeswaran R, Jagadeesh S, et al: Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65:1479-1488, 2005
30. MaPC, Kijima T, Maulik G, et al: c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63:6272-6281, 2003
31. Frampton GM, Ali SM, Rosenzweig M, et al: Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 5:850-859, 2015
32. National Comprehensive Cancer Network: Non-small cell lung cancer, NSCLC-H, version 3.2017. http://www. nccn.org
33. Gautschi O, Milia J, Cabarrou B, et al: Targeted therapy for patients with BRAF-mutant lung cancer: Results from the European EURAF cohort. J Thorac Oncol 10:1451-1457, 2015
34. Hyman DM, Puzanov I, Subbiah V, et al: Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:726-736, 2015
35. Planchard D, Besse B, Groen HJ, et al: Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial. Lancet Oncol 17:984-993, 2016
36. Boulalas I, Zaravinos A, Delakas D, et al: Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder. Int J Biol Markers 24:17-21, 2009
37. Honecker F, Wermann H, Mayer F, et al: Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 27:2129-2136, 2009
38. Kopetz S, Desai J, Chan E, et al: Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 33:4032-4038, 2015
39. Yaeger R, Cercek A, O'Reilly EM, et al: Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 21:1313-1320, 2015
40. Davies BR, Greenwood H, Dudley P, et al: Preclinical pharmacology of AZD5363, an inhibitor of AKT: Pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 11:873-887, 2012
41. Davies BR, Guan N, Logie A, et al: Tumors with AKT1E17K mutations are rational targets for single agent or combination therapy with AKT inhibitors. Mol Cancer Ther 14:2441-2451, 2015
42. Hyman DM, Smyth L, Bedard PL, et al: Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors. Mol Cancer Ther 14:B109, 2015
43. Lee JW, Soung YH, Seo SH, et al: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 12:57-61, 2006
44. Bose R, Kavuri SM, Searleman AC, et al: Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3:224-237, 2013
45. Hyman D, Piha-Paul S, Rodón J, et al: Abstract PD5-05: Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial. Cancer Res 76:PD5-05, 2016
46. Lin J, Sampath D, Nannini MA, et al: Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res 19:1760-1772, 2013
47. de Bono JS, De Giorgi U, Massard C, et al: PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol 27:243-265, 2016
48. Fleming GF, Ma CX, Huo D, et al: Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 136:355-363, 2012
49. Ma CX, Luo J, Naughton M, et al: A phase I trial of BKM120 (buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer. Clin Cancer Res 22:1583-1591, 2016
50. Rodon J, Brana I, Siu LL, et al: Phase I dose-escalation and-expansion study of buparlisib (BKM120), an oral panclass I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 32:670-681, 2014
51. Trédan O, Treilleux I, Wang Q, et al: Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: A GINECO group study. Target Oncol 8:243-251, 2013
52. Yang L, Clarke MJ, Carlson BL, et al: PTEN loss does not predict for response to RAD001 (everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res 14:3993-4001, 2008
53. Nissan MH, Pratilas CA, Jones AM, et al: Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res 74:2340-2350, 2014
54. Naidoo J, Sima CS, Rodriguez K, et al: Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. Cancer 121:3212-3220, 2015
55. Yasuda H, Park E, Yun CH, et al: Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 5:216ra177, 2013
56. Gonzalvez F, Zhu X, Huang W-S, et al: Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models. Cancer Res 76:2644, 2016
57. National Comprehensive Cancer Network: NCCN guidelines, colon cancer, version 2.2017. https://www.nccn.org
58. National Comprehensive Cancer Network:NCCNguidelines, rectal cancer, version 3.2017. https://www.nccn.org
59. National Comprehensive Cancer Network: NCCN guidelines, non-small cell lung cancer, version 5.2017. https:// www.nccn.org
60. National Comprehensive Cancer Network: NCCN guidelines, soft tissue sarcoma, version 2.2017. https://www. nccn.org
61. Jänne PA, Yang JC, KimDW, et al: AZD9291 in EGFRinhibitor-resistant non-small-cell lung cancer.NEngl JMed 372:1689-1699, 2015
62. Bouchet BP, Caron de Fromentel C, Puisieux A, et al: p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol 58:190-207, 2006
63. Lane DP, Cheok CF, Lain S: p53-based cancer therapy. Cold Spring Harb Perspect Biol 2:a001222, 2010
64. Khoo KH, Verma CS, Lane DP: Drugging the p53 pathway: Understanding the route to clinical efficacy. Nat Rev Drug Discov 13:217-236, 2014 [Erratum: Nat Rev Drug Discov 13:314, 2014]
65. Schwaederle M, Zhao M, Lee JJ, et al: Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials. J Clin Oncol 33:3817-3825, 2015
66. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490:61-70, 2012
67. Ciriello G, Gatza ML, Beck AH, et al: Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163: 506-519, 2015
68. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337, 2012
69. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202-209, 2014
70. Aguiar PN Jr, Muniz TP, Miranda RR, et al: Current advances in targeted therapies for metastatic gastric cancer: Improving patient care. Future Oncol 12:839-854, 2016
71. Cercek A, Saltz L: Evolving treatment of advanced colorectal cancer. Curr Oncol Rep 12:153-159, 2010
72. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
73. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
74. Kris MG, Johnson BE, Berry LD, et al: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998-2006, 2014
75. Tsimberidou AM, Wen S, Hong DS, et al: Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: Validation and landmark analyses. Clin Cancer Res 20:4827-4836, 2014
76. Zehir A, Benayed R, Ronak H, et al: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10, 000 patients. Nature Med (in press)
77. Gray SW, Hicks-Courant K, Cronin A, et al: Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol 32:1317-1323, 2014
78. MacArthur DG, Manolio TA, Dimmock DP, et al: Guidelines for investigating causality of sequence variants in human disease. Nature 508:469-476, 2014
79. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405-424, 2015
80. Febbo PG, Ladanyi M, Aldape KD, et al:NCCNtask force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 9:S1-S32, 2011 (suppl 5); quiz S33
81. Hayes DF, Bast RC, Desch CE, et al: Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466, 1996
82. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
83. Conti RM, Bernstein AC, Villaflor VM, et al: Prevalence of off-label use and spending in 2010 among patentprotected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol 31:1134-1139, 2013
84. Fairman KA, Curtiss FR: Regulatory actions on the off-label use of prescription drugs: Ongoing controversy and contradiction in 2009 and 2010. J Manag Care Pharm 16:629-639, 2010
85. Largent EA, Miller FG, Pearson SD: Going off-label without venturing off-course: Evidence and ethical off-label prescribing. Arch Intern Med 169:1745-1747, 2009
86. Corcoran RB, Atreya CE, Falchook GS, et al: Combined BRAF andMEKinhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 33:4023-4031, 2015
87. Langer CJ, Stephenson P, Thor A, et al: Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 22:1180-1187, 2004
88. Jordan EJ, Kim HR, Arcila ME, et al: Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Disc doi: 10.1158/2159-8290. CD-16-1337 [epub ahead of print on March 23, 2017]
89. Bergethon K, Shaw AT, Ou SH, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870, 2012
90. Ou SH, Tan J, Yen Y, et al: ROS1 as a 'druggable' receptor tyrosine kinase: Lessons learned from inhibiting the ALK pathway. Expert Rev Anticancer Ther 12:447-456, 2012
91. Rikova K, Guo A, Zeng Q, et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203, 2007
92. Jänne PA, Shaw AT, Pereira JR, et al: Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14:38-47, 2013
93. Jänne PA, Mann H, Ghiorghiu D: Study design and rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1). Clin Lung Cancer 17:e1-e4, 2016
94. Infante JR, Fecher LA, Falchook GS, et al: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: A phase 1 dose-escalation trial. Lancet Oncol 13:773-781, 2012
95. Rinehart J, Adjei AA, Lorusso PM, et al: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456-4462, 2004
96. Hu-Lieskovan S, Mok S, Homet Moreno B, et al: Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 7:279ra41, 2015
97. Kakavand H, Wilmott JS, Menzies AM, et al: PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor-treated melanoma patients. Clin Cancer Res 21:3140-3148, 2015
98. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372: 2509-2520, 2015
99. Loi S, Dushyanthen S, Beavis PA, et al: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res 22:1499-1509, 2016
100. Yoon YK, Kim HP, Han SW, et al: KRASmutant lung cancer cells are differentially responsive toMEKinhibitor due to AKT or STAT3 activation: Implication for combinatorial approach. Mol Carcinog 49:353-362, 2010